Navigation Links
Promacta in Medical News

GlaxoSmithKline Files for FDA Approval of PROMACTA(TM) (eltrombopag) to be the First Oral Platelet Growth Factor for Rare Blood Disorder

... Application Data Show promacta Significantly Raised Platelet Counts and Lowered B... to support the NDA and hopeful that, if approved, promacta may provide physicians and chronic ITP patients wi...ointestinal or intra cerebral bleeds.(1) About promacta (eltrombopag) Eltrombopag is an oral, non-peptid...

GlaxoSmithKline Presents Innovative Neuroscience Pipeline

... vaccine Seretide TORCH Volibris (EU) Ofatumumab (RA) (EU) Tykerb (US) Requip XL (PD) (US) promacta (hep c) Wellbutrin XR (EU) Rotarix (US) Tykerb (H&N cancer) Tykerb + Pazopanib ...
Promacta in Medical Technology

Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP

VIENNA, Austria, June 11, 2007 /PRNewswire/ -- GlaxoSmithKline plc announced results from an international, pivotal Phase III study of its investigational non-peptide oral platelet growth factor, PROMACTA(R) (eltrombopag olamine). Data from this study showed that PROMACTA at 50-75mg once daily res...

GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP

...ne or more prior ITP therapies. Patients receiving promacta were eight times more likely than those on placebo... treatments that can help improve patients' lives. promacta is a great example of this commitment." promacta received accelerated approval from the FDA on Nove...

FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder

...ctomy. The approval is a significant milestone for promacta and the ITP community, as promacta is the first oral thrombopoietin (TPO) receptor ag...d for adult patients with chronic ITP. GSK expects promacta to be available by the next week. "It is ...

FDA Grants Priority Review for PROMACTA(R) (eltrombopag)

...chronic idiopathic thrombocytopenic purpura (ITP). promacta is an investigational, once-daily oral treatment t...dence of bleeding in chronic ITP. If approved, promacta would be the first oral thrombopoeitin (TPO) recep...elet counts and reduce bleeding. "Our goal for promacta is to make available a targeted therapy in oral fo...

Long-Term Safety and Efficacy Data on Promacta(TM) (Eltrombopag) Presented at American Society of Hematology Annual Meeting

...Hematology, December 8-11 2007 in Atlanta, GA. promacta is an investigational compound that has not receiv...in any market for any indication at this time. promacta was generally well tolerated in this study. Of the...ITP in the U.S.(5) and a similar number in Europe. promacta is an investigational oral, non-peptide, platelet ...
Promacta in Biological News

Lancet study supports new, highly effective treatment for blood disorder

...d, rarely, life-threatening brain hemorrhages. promacta (eltrombopag) was granted accelerated approval by ...y testing period, 59 percent of subjects receiving promacta achieved platelet counts at or over 50,000 per L o...count is between 30,000 and 50,000 per L of blood. promacta subjects were almost 10 times more likely to reach...

Eltrombopag effective for hepatitis C patients with low blood-platelet counts

...orts equity ownership in the company.) The current study was sponsored by GlaxoSmithKline, which is developing eltrombopag. Eltrombopag (marketed as promacta in the U.S. and Revolade in Europe) is an investigational oral, non-peptide platelet growth factor that induces the proliferation and differentiation ...
Other Tags
(Date:6/3/2015)... (PRWEB) June 03, 2015 The Canton ... transforms businesses with technology, announced today that Tim Dodge ... Mr. Dodge joins The Canton Group as ... of successful customer engagements. , Tim is a tech ... for a variety of technology companies. Before joining The ...
(Date:6/3/2015)... Seattle, WA (PRWEB) June 03, 2015 On ... for the majority of genetic drug sensitivity (pharmacogenetic) testing that ... expected to impact as many as 19 million of the ... special risk of costly and life-threatening adverse drug events.(1) Sadly, ... save Medicare millions. , Precision Medicine, the use of an ...
(Date:6/3/2015)... June 03, 2015 Horizon Blue Cross Blue ... Magazine as one of the nation’s top employers for diverse ... 6 among its national list of Best Places for Diverse ... the No. 1 Regional Company. This is the sixth ... MBA Magazine for its diverse workplace policies and programs. , ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 A group ... be honored with a Global Inspire Award at DIA’s ... the organization’s outstanding volunteers for their leadership, level of ... , The recipients of the Author(s) of ... of authors whose article has made a significant impact ...
(Date:6/3/2015)... Visual BI Solutions, a leader in ... launch of the second release of its successful ... Studio. The Design Studio EXtension suite allows customers ... into their dashboarding projects. , With the second ... adding key components for customers that are looking ...
Breaking Medicine News(10 mins):Health News:The Canton Group Appoints Tim Dodge as Chief Marketing Officer 2Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 2Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 3Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 4Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 5Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 6Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 7Health News:Horizon Blue Cross Blue Shield of New Jersey Named a 2015 Best Place for Diverse Managers and Women to Work by Diversity MBA Magazine 2Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 2Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 3Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 4Health News:Visual BI Launches Second Release for its Design Studio EXtensions (DSX) for SAP® BusinessObjects™ Design Studio 2Health News:Visual BI Launches Second Release for its Design Studio EXtensions (DSX) for SAP® BusinessObjects™ Design Studio 3
(Date:4/27/2015)... 27, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market, announces that ... customers the first week of May, 2015 and will ... May. Gino Pereira , Chief ... the company as Wocket® enters the consumer market. We ...
(Date:4/21/2015)... High crime rate, increasing ... access control systems market in Saudi Arabia ... published report by TechSci Research " Saudi Arabia Access Control ... systems market in Saudi Arabia ... control systems market in the Kingdom is growing at ...
(Date:4/20/2015)... -- The announcement comes as demand for ... (GRM), Ireland,s foremost records management company, ... up an impressive track record of clients within the first ... records management sector in Dubai . As ... and employ a further eight staff members at its Irish ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3
Other Contents